Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

clinical trial

Details

Instance of: clinical trial
Start time: 23 February 2016
End time: December 2019
Country: United States
Main subject: hematopoietic system disease
clinical trial phase: phase II clinical trial
minimum age: 18
number of participants: 64
research intervention: sirolimus
study type: interventional study
title: A Phase II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention

Nothing in the MetaHistoryBook collection references this item yet.